Clinical Trials Browser

Enrolling by invitation × Interventional × S 1 (combination) × Clear all

NCT06901622 2025-03-30

Camrelizumab and Chemotherapy With or Without Anlotinib as First-line Treatment for Advanced Gallbladder Cancer and Extrahepatic Cholangiocarcinoma

Phase 2 Enrolling by invitation

Gastrointestinal

Gallbladder Neoplasms, Cholangiocarcinoma